Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Total Current Liabilities (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Total Current Liabilities for 9 consecutive years, with $14.4 million as the latest value for Q1 2024.

  • On a quarterly basis, Total Current Liabilities fell 6.92% to $14.4 million in Q1 2024 year-over-year; TTM through Mar 2024 was $14.4 million, a 6.92% decrease, with the full-year FY2023 number at $13.7 million, down 11.47% from a year prior.
  • Total Current Liabilities was $14.4 million for Q1 2024 at SELLAS Life Sciences, up from $13.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $15.5 million in Q4 2022 to a low of $4.2 million in Q2 2021.
  • A 5-year average of $11.1 million and a median of $13.4 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: tumbled 59.61% in 2021, then soared 211.42% in 2022.
  • SELLAS Life Sciences' Total Current Liabilities stood at $12.3 million in 2020, then crashed by 59.61% to $5.0 million in 2021, then skyrocketed by 211.42% to $15.5 million in 2022, then dropped by 11.47% to $13.7 million in 2023, then rose by 5.11% to $14.4 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Total Current Liabilities are $14.4 million (Q1 2024), $13.7 million (Q4 2023), and $13.4 million (Q2 2023).